GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Q2 FY27 Standalone Net Profit at Rs. 3,913.47 Lakhs

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 04 Nov 2026, 01:27 PM IST  ·  BSE ID: dc433954-8a55-47c1-98d6-6fba6e464d1e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company reported its latest financial results, showing a net profit of Rs. 3,913.47 Lakhs, and also changed its Company Secretary.
🤖 AI Summary
  • Standalone net profit for SMS Pharmaceuticals in Q2 FY27 was Rs. 3,913.47 Lakhs.
  • Revenue from operations stood at Rs. 31,607.41 Lakhs for the quarter ended September 30, 2026.
  • Mr. Thirumalesh Tumma resigned as Company Secretary and Compliance Officer, effective November 4, 2026.
  • Mr. Manohar Mollama was appointed as the new Company Secretary and Compliance Officer, effective November 5, 2026.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Revenue from Operations (Q2 FY27)
Rs. 31,607.41 Lakhs
30.38
Standalone Net Profit After Tax (Q2 FY27)
Rs. 3,913.47 Lakhs
55.65
Standalone Revenue from Operations (H1 FY27)
Rs. 52,303.90 Lakhs
19.29
Standalone Net Profit After Tax (H1 FY27)
Rs. 6,026.73 Lakhs
39.04
Basic/Diluted EPS (Q2 FY27)
Rs. 4.18
48.23
🏢 How This Affects the Company
📈
Business Impact
The increase in revenue from operations to Rs. 31,607.41 Lakhs indicates an expansion in sales for the quarter.
💰
Financial Impact
Net Profit after Tax of Rs. 3,913.47 Lakhs for Q2 FY27 contributes to the company's accumulated earnings. Cash and Cash Equivalents decreased to Rs. 3,599.40 Lakhs as of September 30, 2026, from Rs. 4,578.15 Lakhs as of March 31, 2026.
⚙️
Operational Impact
The change in Company Secretary and Compliance Officer results in a transition in key managerial personnel, ensuring regulatory compliance functions remain staffed.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance. The change in Company Secretary does not directly impact shareholder holdings or rights.
🔍
Management Signal
The Board's approval of the financial results and prompt appointment of a new Company Secretary signals a focus on maintaining corporate governance and regulatory compliance.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Q3 FY27 results — evaluate revenue and profit growth sustainability.
Updates on the new Company Secretary's integration and compliance activities.
Cash flow statements for future periods to assess working capital and investment patterns.
MEDIUM RISK While profit growth is strong, cash outflow from investing activities and reduced cash balance warrant monitoring.
💡 Investor Takeaway
SMS Pharmaceuticals reported a standalone Net Profit of Rs. 3,913.47 Lakhs in Q2 FY27, a 55.65% increase from Rs. 2,514.30 Lakhs in Q2 FY26. Revenue from Operations for the quarter ended September 30, 2026, rose 30.38% to Rs. 31,607.41 Lakhs from Rs. 24,242.95 Lakhs in the prior year.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Revenue from Operations increased to Rs. 31,607.41 Lakhs in Q2 FY27 from Rs. 24,242.95 Lakhs in Q2 FY26, a 30.38% rise.
  • Standalone Net Profit after Tax grew to Rs. 3,913.47 Lakhs in Q2 FY27 from Rs. 2,514.30 Lakhs in Q2 FY26, a 55.65% increase.

⚠️ Concerns

  • Net cash outflow from investing activities was Rs. (8,607.73) Lakhs for the half year ended September 30, 2026, driven by Property, Plant and Equipment purchases.
  • Cash and Cash Equivalents at the end of the period decreased to Rs. 3,599.40 Lakhs from Rs. 4,578.15 Lakhs at the beginning of the financial year.
📅 Company Track Record
SMS Pharmaceuticals reported Q1 FY27 revenue growth of 6% YoY to ₹207.0 Cr, with PAT up 8% YoY. Earlier filings showed Q2 FY27 PAT up 57% to ₹39.57 crore and revenue grew 30% YoY, which aligns with the current filing's details of Rs. 3,913.47 Lakhs net profit and Rs. 31,607.41 Lakhs revenue.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was SMS Pharmaceuticals' standalone net profit in Q2 FY27?
SMS Pharmaceuticals reported a standalone net profit after tax of Rs. 3,913.47 Lakhs for the quarter ended September 30, 2026 (Q2 FY27).
What was SMS Pharmaceuticals' standalone revenue from operations in Q2 FY27?
The standalone revenue from operations for SMS Pharmaceuticals in Q2 FY27 was Rs. 31,607.41 Lakhs.
What was the year-on-year growth in standalone net profit for SMS Pharmaceuticals in Q2 FY27?
Standalone Net Profit after Tax grew by 55.65% in Q2 FY27, from Rs. 2,514.30 Lakhs in Q2 FY26 to Rs. 3,913.47 Lakhs in Q2 FY27.
Who has been appointed as the new Company Secretary for SMS Pharmaceuticals?
Mr. Manohar Mollama (ICSI M.No. F11904) has been appointed as the new Company Secretary & Compliance Officer of SMS Pharmaceuticals, effective November 5, 2026.
What was the Basic/Diluted Earnings Per Share for SMS Pharmaceuticals in Q2 FY27?
The Basic/Diluted Earnings Per Equity Share for SMS Pharmaceuticals was Rs. 4.18 for Q2 FY27.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.